Introduction: A large-scale clinical trial, the Sequence Trial Alternatives to Relieve Depression (STAR*D) study, concluded that about one-third of the studied patients with major depressive disorder remitted during the initial treatment with selective serotonin reuptake inhibitors and that approximately half of the remitted subjects relapsed over a 1-year follow-up. The development of new therapeutic approaches with potent efficacy and good tolerability for the treatment of depressive disorders is of great importance. Adult hippocampal neurogenesis has been proposed to be important for understanding and treating depression and anxiety. The present study aimed to elucidate whether or not 5-hydroxytryptamine 1A (5-HT1A) receptor partial agonists have a potential therapeutic effect for the treatment of depressive and anxiety disorders, from the standpoint of neurogenesis. Methods: Male Sprague-Dawley rats were subcutaneously administered a vehicle or tandospirone (TDS) (1 or 10 mg/kg) once daily for 14 days. The effects of chronic TDS treatment on neurogenesis were evaluated on the day after the last injection. The quantification of hippocampal neurogenesis was estimated using immunostaining with doublecortin (DCX), a marker protein of newborn neurons. Results: Chronic TDS treatment resulted in a significant increase in the number of DCXpositive cells per volume of dentate gyrus in a dose-dependent manner. Conclusion: The results strongly suggest that 5-HT1A receptor partial agonists would be useful and beneficial in the treatment of depressive and anxiety disorders through increased hippocampal neurogenesis. Depression and anxiety; Dose dependent; Doublecortin; Hippocampal neurogenesis; Novelty suppressed feeding; Tandospirone
INTRODUCTION
Depression and anxiety are common public health problems, affecting 5-10% of the world's population at any given time, and they share a high degree of comorbidity (up to 80-90%) [1] . Although there are a number of medications available for the treatment of depressive and anxiety disorders, a considerable number of patients cannot achieve remission [2] . The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a large-scale clinical trial for major depressive disorder (MDD), demonstrated that only about one-third of the participants remitted during the initial treatment with citalopram and that approximately half of the remitted participants relapsed over a 1-year follow-up [3] [4] [5] . Baldwin et al. [6] , in a review of previous studies of pharmacotherapies for generalized anxiety disorder (GAD), concluded that the remission rate is less than 60% for GAD patients treated with selective serotonin reuptake inhibitors (SSRIs). Therefore, the development of effective new therapeutic approaches with good tolerability for the treatment of depressive and anxiety disorders is of great importance.
Adult hippocampal neurogenesis has been proposed as important for understanding and treating depression and anxiety [7] . The hippocampus is not only involved in cognitive functions, but also is a key structure for regulating affective and anxiety states. The subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus is one of only a few brain regions where the production of new neurons occurs throughout the lifetime of animals, including humans [8, 9] .
Accumulating evidence shows that adult hippocampal neurogenesis is decreased by stress and increased by chronic administration of antidepressants, such as fluoxetine [10, 11] .
Thus, changes in adult hippocampal neurogenesis may be related to the pathophysiology of depressive and anxiety disorders and to the beneficial effects of antidepressant treatment [7, 9, 12, 13] .
The azapirone drugs, including buspirone, tandospirone (TDS), and gepirone which act as 5-hydroxytryptamine 1A (5-HT1A) receptor partial agonists, have been widely used in the treatment of anxiety disorder [14, 15] . In practice, benzodiazepines are most frequently used in combination with standard antidepressants for the initial treatment and maintenance therapy for depressive disorders when comorbid anxiety exists [16] . We and many other researchers have shown that benzodiazepines produce drug dependence, sedation, and cognitive impairment in humans and rodents [17] [18] [19] [20] . In contrast, azapirone-type 5-HT1A receptor agonists have the advantage of producing significantly fewer adverse effects than benzodiazepines and result in little dependence [21] [22] [23] . Recently, two animal studies revealed that co-administering benzodiazepines with antidepressants prevents an SSRI-induced increase in hippocampal neurogenesis, which suggests that the use of benzodiazepines delays the therapeutic onset and reduces the clinical efficacy of SSRIs [24, 25] . In contrast to above reports concerning benzodiazepines, 5-HT1A receptor agonists are considered to have an augmenting effect on clinical efficacy for depressive disorders when administered in combination with an SSRI. Recently, several authors have reported that augmentation therapy consisting of a combination of antidepressants with 5-HT1A receptor agonist treatment is a better therapeutic strategy for MDD than antidepressant monotherapy [3, 26, 27] . In our previous pilot study, we showed that TDS, the only azapirone drug available in Japan, has excellent clinical efficacy for the treatment of GAD and mixed anxiety-depression and that it has no significant adverse effects [28] . We also showed that TDS had a remarkable anxiolytic effect in an animal model of anxiety and that the potency of the pharmacological effect was increased dose dependently, without a sedative effect [23] . Based on previous reports by many authors and our studies described above, we hypothesize that hippocampal neurogenesis plays an important role in the clinical efficacy of 5-HT1A receptor partial agonists.
This study aimed to elucidate the potential therapeutic effect of 5-HT1A receptor partial agonists in the treatment of depressive and anxiety disorders, from the standpoint of neurogenesis.
METHODS

Animals
Male Sprague-Dawley rats (Kyudo Co., LTD., Tosu, Japan) weighing 150-200 g upon arrival were studied. They were housed individually in a temperature (23 ± 2°C), humidity (60 ± 10%), and light-controlled room (reverse 12-h light/dark cycle, lights off at 7:00 a.m.). Food and water were available ad libitum. All animal care and use procedures were performed in compliance with the regulations established by the Experimental Animal Care and Use Committee of Fukuoka University, which are in accordance with the universal principles of laboratory animal care.
Drugs
Tandospirone citrate was supplied by Dainippon Sumitomo Pharma Co., Ltd.
(Osaka, Japan). The drug was dissolved in saline and prepared at a concentration of 1 or 10 mg/mL, then injected subcutaneously in a volume of 1 mL/kg. The control animals were given the same volume of vehicle solution. The dosage of TDS was chosen on the basis of previous reports [23, 33] . One week following the arrival of the animals at the laboratory, they were injected with either the vehicle or TDS (1 or 10 mg/kg) once daily for 14 days.
Novelty Suppressed Feeding (NSF) test
Novelty Suppressed Feeding test was performed as previously described [34] [35] [36] . Briefly, animals were fasted for 24 h, then placed in a corner of a large polypropylene tub (50 9 40 9 20 cm) with a food pellet positioned in the center. sampling scheme was considered adequate when CE was less than 0.10 [38] .
Statistical Analysis
One-way factorial analysis of variance (ANOVA) was performed to test for differences in latency in the NSF test and for quantification of DCXpositive cells, followed by Bonferroni/Dunn post hoc analysis for further examination of group differences. For the NSF test, the Kaplan-Meier method with Mantel-Cox log-rank test was used to determine differences in survival curves where the latency to eat was the limit of survival as previously described [25] . All data are represented as mean ± standard error of the mean (SEM). P value of \0.05 was adopted for significance.
RESULTS
The Effects of Tandospirone in the NSF test
The acute effect of TDS in the NSF test was examined immediately after the first injection of vehicle or TDS. TDS-treated animals performed significantly better than the vehicle-treated group (Kaplan-Meier survival analysis, Mantel-Cox log-rank test, P = 0.0145; Fig. 1a , One-way ANOVA, F 2, 10 = 5.753, P = 0.0217; Fig. 1b ). Post hoc analysis further showed that acute treatment with high-dose TDS (10 mg/kg) produced a significant decrease in the latency to feeding relative to the vehicle-(P = 0.0080) and TDS (1 mg/kg)-treated rats (P = 0.0370). On the contrary, chronic TDS treatment did not have any behavioral effect on the latency to feeding compared with the vehicle-treated group (Fig. 1c, d) .
The Effects of Tandospirone on DCX-
Positive Cells in the Dentate Gyrus of the Hippocampus
Because of technical problems, brain samples for immunohistochemistry analysis could not be taken from three animals (one vehicletreated group, one TDS 1 mg/kg-treated group and one TDS 10 mg/kg-treated group). DCX is a protein expressed in immature newly born neurons that has recently been utilized to assess the level of neurogenesis [39, 40] . To assess the potential of TDS to modulate hippocampal neurogenesis, the number of DCX-immunopositive cells in the DG of the hippocampus was evaluated. Representative images of doublecortin-positive cells are shown in Fig. 2 . DCX-labeled cells were observed mainly at the border of the GCL in the DG of the hippocampus (Fig. 2) . The number of DCX-positive cells per volume of DG was significantly increased in the TDStreated group compared with the vehicletreated group (F 2, 7 = 17.853, P = 0.0018; Fig. 3 ). Post hoc analysis identified significant differences between the vehicle-treated group and both the low and high dosage TDS-treated groups (P = 0.0155, P\0.001, respectively) and between the TDS (1 mg/kg) and TDS (10 mg/ kg)-treated groups (P = 0.0368). However, no significant relationships between the number of DCX-labeled cells in the DG and the latency to feeding in the NSF test were found in the correlational analysis (data not shown).
DISCUSSION
In the present study, administration of TDS for 14 days increased the number of DCX-positive cells in the DG of adult rat hippocampus in a dose-dependent manner. This result suggests that chronic treatment with TDS increases hippocampal neurogenesis in humans, because DCX can be used as a quantitative marker of new nerve cells in the adult brain [39, 40] . Adult hippocampal neurogenesis has been shown to be important for understanding and treating depression and anxiety [7] . Based on our result, we propose that 5-HT1A receptor partial agonists would be of great clinical usefulness for the treatment of depressive and anxiety disorders because of increased hippocampal neurogenesis. However, it will also be necessary in future studies to use other markers, such as Ki-67, NeuroD or NeuN, at each stage of neurogenesis and to assess the maturation index and synaptic branching in The anxiolytic effect of 5-HT1A receptor partial agonists has been established and it has been shown that 5-HT1A receptor partial agonists have no remarkable adverse effects and little dependency. Furthermore, previous clinical trials suggest the possibility of 5-HT1A receptor partial agonists as useful drugs for the treatment of schizophrenia, eating disorders, Parkinson's disease, and cognitive dysfunction [41] [42] [43] [44] [45] [46] . Recently, hippocampal neurogenesis has been associated with the etiology and treatment of neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease [47] . Also, Barbarich-Marsteller et al. [48] reported that hippocampal cell proliferation in the DG was reduced in an animal model of anorexia nervosa. Our results suggest the clinical usefulness of 5-HT1A receptor partial agonists for the treatment of such important diseases as those described above.
5-HT1A receptor partial agonists can also be used as augmentation therapy in conjunction with antidepressants for the treatment of depressive disorder [3] . Recent animal studies indicate that co-administering benzodiazepines with antidepressants prevents the SSRI-induced increase in hippocampal neurogenesis, although benzodiazepines are often used as anxiolytics in combination with antidepressants for depressive disorders, especially in the early phases of therapy when comorbid anxiety is present [16, 24, 25] . In contrast, our result suggesting that TDS treatment induces an increase in hippocampal neurogenesis helps explain the augmenting effect of 5-HT1A receptor partial agonists on their clinical efficacy for depressive disorders when administered in combination with an SSRI. In the present study, acute treatment with TDS significantly decreased the latency to feeding in the NSF test. The NSF test assesses anxiety behavior by measuring the time it takes an animal to approach and eat a familiar food in an aversive environment. Also, the NSF test is considered to be very sensitive to chronic treatment with antidepressants, including SSRIs [35] . Although it is difficult to prove that acute treatment with TDS exerts the same anxiolytic effect as chronic antidepressant treatment, this result suggests that TDS has specific efficacy for anxiety disorders. We also showed the anxiolytic effect of TDS using conditioned fear stress-induced freezing behavior in a previous study [23] . Thus, we have shown the excellent anxiolytic effect of TDS using two unique rodent models of anxiety behavior. 
CONCLUSION
In conclusion, this study strongly suggests that 5-HT1A receptor partial agonists are useful and beneficial for the treatment of depressive and anxiety disorders, from the standpoint of hippocampal neurogenesis.
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